This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

TD-6450 SAD and MAD in Healthy Subjects

This study has been completed.
Information provided by (Responsible Party):
Theravance Biopharma R & D, Inc. Identifier:
First received: December 17, 2013
Last updated: September 25, 2014
Last verified: September 2014
This study consists of two parts, Parts A and B. Part A is a single ascending dose (SAD) study in healthy subjects. Part B is a multiple ascending dose (MAD) study in healthy subjects.

Condition Intervention Phase
Hepatitis C Drug: TD-6450 Drug: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blinded, Randomized, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of TD-6450, a NS5A Inhibitor, in Healthy Subjects

Resource links provided by NLM:

Further study details as provided by Theravance Biopharma R & D, Inc.:

Primary Outcome Measures:
  • Adverse events [ Time Frame: 28 days max ]

Secondary Outcome Measures:
  • Cmax [ Time Frame: 28 days max ]

  • Tmax [ Time Frame: 28 days max ]

  • AUC [ Time Frame: 28 days max ]

  • T1/2 [ Time Frame: 28 days max ]

  • Food effect on AUC value [ Time Frame: 15 days max ]
    Measure difference between fasted and fed doses

Enrollment: 111
Study Start Date: February 2014
Study Completion Date: September 2014
Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: SAD TD-6450
Single ascending dose (Part A)
Drug: TD-6450 Drug: Placebo
Placebo Comparator: MAD TD-6450
Multiple ascending dose (Part B)
Drug: TD-6450 Drug: Placebo
Active Comparator: Food effect of TD-6450
Food effect will be assessed in Part A (SAD) of this study.
Drug: TD-6450


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subject is a female of non-childbearing potential or male, who is healthy, nonsmoking, and 18 to 60 years old, inclusive, at screening. Females are considered to be of non childbearing potential if they have had a hysterectomy or tubal ligation (documentation required) or are postmenopausal (amenorrheic for at least 2 years) with a follicle stimulating hormone (FSH) level >40 IU/L
  • Subject has a body mass index 18 to 30 kg/m2, inclusive, and weighs at least 50 kg.

Exclusion Criteria:

  • Subject has evidence or history of clinically significant allergic (except for untreated, asymptomatic, seasonal allergies at time of dosing), hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease.
  • Subject has an estimated creatinine clearance of <90 mL/min at Screening or Day -1, calculated using the Cockcroft-Gault equation.
  • Subject has participated in another clinical trial of an investigational drug (or medical device) within 60 days prior to Screening, or is currently participating in another trial of an investigational drug (or medical device).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02022306

United States, Texas
ICON Development Solutions
San Antonio, Texas, United States, 78209
Sponsors and Collaborators
Theravance Biopharma R & D, Inc.
  More Information

Responsible Party: Theravance Biopharma R & D, Inc. Identifier: NCT02022306     History of Changes
Other Study ID Numbers: 0094
Study First Received: December 17, 2013
Last Updated: September 25, 2014

Keywords provided by Theravance Biopharma R & D, Inc.:
Hepatitis C

Additional relevant MeSH terms:
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Flaviviridae Infections
RNA Virus Infections processed this record on August 21, 2017